TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04082715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbidopa/levodopa and celecoxib
Description: Every patient of this arm will get one bottle of carbidopa/levodopa and one bottle of celecoxib. At treatment initiation, Carbidopa/Levodopa will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with carbidopa/levodopa twice daily for 3 days and then once daily for 3 days before discontinuing it completely.Celecoxib will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo1 and celecoxib
Description: Every patient of this arm will get one bottle of placebo1 and one bottle of celecoxib. At treatment initiation, placebo1 will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with placebo1 twice daily for 3 days and then once daily for 3 days before discontinuing it completely. Celecoxib will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo1 and placebo2
Description: Every patient of this arm will get one bottle of placebo1 and one bottle of placebo2. At treatment initiation, placebo1 will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with placebo1 twice daily for 3 days and then once daily for 3 days before discontinuing it completely. placebo2 will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
Study: NCT01926795

Intervention type: PROCEDURE
Group type: OTHER
Intervention: No Immobilization
Study: NCT03369938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training intervention
Description: structured aerobic endurance/resistance training on top of usual care for 12 weeks (3x/week)
Study: NCT00712296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASHMI 4
Description: 4 capsules orally twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASHMI 12
Description: 12 capsules orally twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 6 capsules twice a day
Study: NCT04431037

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Early oral feeding/Enhanced recovery after surgery protocols
Description: Early oral feeding refers to NG tube and foley's catheter removed within 12 hours and patients allowed oral sips on day 1 with gradual shift to liquid diet after 12 hrs and semisolid food started after 24 hours later.Patients were given i/v antibiotics,painkillers and i/v PPIs and shifted to oral pain killers on 2nd POD.
Study: NCT01483196

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound imaging
Description: Undergo TCD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Complete neurocognitive questionnaires

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: assessment of therapy complications
Description: Undergo TCD

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Undergo MRI
Study: NCT00586469

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluviral
Description: One dose, Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluviral
Description: One dose, Intramuscular injection
Study: NCT00578500

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ovarian transplantation
Description: Patients will undergo laparoscopic oophorectomy, aspiration of oocytes and maturation followed by cryopreservation. In case of ovarian failure and approval by treating physicians, restoration of fertility will be attempted by thawing of oocytes or by transplantation of ovarian cortex to induce ovulation and obtain oocytes for fertilization and embryo transfer.
Study: NCT00494572

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: 10 mg rapid dissolving granule in sterile water orally once
Study: NCT01945866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone intravitreal implant
Description: The dexamethasone intravitreal injection will be given within 0-8 days of the ranibizumab injection. If defined criteria are met, a second dexamethasone injection in combination with intravitreal ranibizumab (within 0-8 days) will be given at the 12 week visit. If the injections are given consecutively on the same day, the ranibizumab injection must be given first.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham injection
Description: No injection is given. It is a sham injection to keep the participant masked. The sham injection will be given within 0-8 days of the ranibizumab injection. If the injections are given consecutively on the same day, the sham injection must be given first.
Study: NCT03326882

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Study: NCT00649220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: memantine tablets, twice a day (bid), for 20 weeks
Study: NCT01863108

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GeniusVac-Mel4
Description: Multiple sub-cutaneous injections (1 injection weekly during 3 weeks) of GeniusVac-Mel4 (3 increasing dose groups) in patients with melanoma
Study: NCT02847663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kryosauna Space Cabin
Description: The whole body cryotherapy device is able to generatue temperatures up to -195°C for 3 minutes. In this study, we generate temperatures of -135°C for 2 minutes as proposed in the manual. The participant will enter the cabin in cold-resistant shoes and will remain in standing position during the whole procedure. The cold temperature is generated by vaporization of liquid nitrogen.

Intervention type: OTHER
Group type: OTHER
Intervention: cold water tub
Description: The tub will be filled with cold water up to the sternal level of the participants. Adding ice will ensure a constant temperature. The participant will sit inside the tub during the whole procedure.
Study: NCT01154530

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Mouthwash with a 0,2 % chlorhexidine solution for 30 seconds
Study: NCT01415141

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: 180ug subcutaneously, weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: 180ug subcutaneously, weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Administered orally twice a day as follows:~weight \< 75kg - 1000mg weight ≥ 75kg - 1200mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Administered orally twice a day as follows:~weight \< 75kg - 1000mg weight ≥ 75kg - 1200mg
Study: NCT03109210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Cognitive Behavioral Therapy (OCBT)
Description: Cognitive behavioral therapy delivered via commercial online software.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-directed Cognitive Behavioral Therapy (TCBT)
Description: Cognitive Behavioral Therapy delivered via traditional, in-person interaction with a licensed mental health professional.
Study: NCT00496691

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based HIV prevention program
Description: comparison between parent-child intervention targeting parent-teen sexual communication, condom use skills, and assertiveness training to an adolescent-only intervention that targets similar constructs minus parent-teen sexual communication and a general health promotion intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-based HIV prevention program
Description: comparison between parent-child intervention targeting parent-teen sexual communication, condom use skills, and assertiveness training to an adolescent-only intervention that targets similar constructs minus parent-teen sexual communication and a general health promotion intervention
Study: NCT03046888

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot assisted pyelolithotomy
Description: A 12-mm camera port is placed at the level of the umbilicus and lateral; this port is moved farther laterally in morbidly obese patients to allow for the instruments to reach the target organs. Two 8-mm robotic trocars are placed under direct vision and a 12-mm assistant port is placed in the midline a 5-8 cm above the umbilicus. For right-sided stones, an additional 5-mm port is placed in the midline just below the xiphoid process for liver retraction. Placement of the trocars can be changed according to surgeon preference. After reflecting the colon medially, the renal pelvis will be dissected and identified, a flexible cystoscope will be inserted via an assisted trocar and introduced into the renal pelvis through a minor incision. The kidney stones will then be extracted with a basket and either removed via the port or placed in a specimen retrieval bag.
Study: NCT00496691

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Family-based HIV prevention program
Description: comparison between parent-child intervention targeting parent-teen sexual communication, condom use skills, and assertiveness training to an adolescent-only intervention that targets similar constructs minus parent-teen sexual communication and a general health promotion intervention
Study: NCT01246193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828(FDC)
Description: Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
Study: NCT01415141

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telaprevir
Description: 750mg every 8 hours, orally
Study: NCT01726582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milestone 1: Targeted chemotherapy prior to surgery
Description: The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
Study: NCT00765791

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Neck Dissection Excluding Level 2B
Description: Selective neck dissection is performed. Level 2a is dissected; level 2b is not dissected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Neck Dissection Including Level 2B
Description: Selective neck dissection is performed. Level 2a is dissected; level 2b is also dissected.
Study: NCT02604199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520 Injection
Description: ARC-520 Injection was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520 Injection
Description: ARC-520 Injection was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: entecavir
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: entecavir
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
Study: NCT00270244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group interpersonal psychotherapy for depressed adolescents (IPT-AG)
Description: Participants assigned to IPT-AG will attend two to three, 40-minute individual pre-group sessions, followed by 12, 90-minute group therapy sessions and two additional individual sessions-one midway through the group sessions and another upon completion of group therapy. Sessions will focus on problems in interpersonal relationships.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: TAU will consist of counseling sessions as regularly conducted by the school clinic social worker and/or referral to another agency.
Study: NCT02604199

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tenofovir
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tenofovir
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antihistamine
Description: All participants will be pretreated with an oral antihistamine, administered 2 hours (±30 minutes) pre-dose. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antihistamine
Description: All participants will be pretreated with an oral antihistamine, administered 2 hours (±30 minutes) pre-dose. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: antihistamine
Description: All participants will be pretreated with an oral antihistamine, administered 2 hours (±30 minutes) pre-dose. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: antihistamine
Description: All participants will be pretreated with an oral antihistamine, administered 2 hours (±30 minutes) pre-dose. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
Study: NCT04182451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Meso Wound Matrix
Description: Subjects who meet eligibility criteria will receive standard of care and Meso Wound Matrix.~The standard of care therapy in this study is offloading of the DFU, appropriate sharp or surgical debridement, and aggressive infection management with the use of appropriate dressings. Total contact casting or fixed ankle walker will be used for off-loading. Wound Matrix is an acellular scaffold to reinforce and repair soft tissue defects. Subjects may receive up to eight applications of Meso Wound Matrix. Subjects whose study ulcer does not heal after eight applications will receive only SOC treatment for 4 additional weeks.
Study: NCT03679689

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: artificially sweetened beverages
Description: artificially sweetened beverages restriction
Study: NCT01277302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Liquid ranibizumab (10 mg/ml) was supplied in a sterile solution in single-use vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Liquid ranibizumab (10 mg/ml) was supplied in a sterile solution in single-use vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Liquid ranibizumab (10 mg/ml) was supplied in a sterile solution in single-use vials.
Study: NCT02233075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REP 2139-Ca + Pegasys (TM)
Description: 15 weeks of REP 2139-Ca (500mg QW IV) followed by: 15 weeks of REP 2139-Ca (250mg QW IV) + Pegasys(TM) (180 ug QW SC) followed by: 33 weeks of Pegasys(TM) (180 ug QW SC)
Study: NCT00965471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cipher prescription 1
Description: Drug granules include ginseng,RADIX NOTOGINSENG,prepared RHIZOMA PINELLIAE with alumen radix glyrrhigae calcaren once daily for 180 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cipher prescription 2
Description: Placebo include amidon、bitter principles and diluents bases once daily for 180 days
Study: NCT02042118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway
Description: Laryngeal mask airway (LMA) ventilation will be provided for newborns in this arm during the first 2.5 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Face mask ventilation
Description: Face-mask ventilation (FMV) will be provided for newborns in this arm during the first 2.5 minutes.
Study: NCT01197352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational and Normative Feedback
Description: Weekly feedback based on their frequency and degree of at-risk drinking behavior using normative, educational and motivational feedback

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Awareness
Description: Weekly queries to raise awareness and allow self-reflection about drinking habits
Study: NCT05620446

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopy
Description: the technique was done by two doctor the patients were sedated then colonoscopy was done for the patients while the patients were put in lithotomy position , we identified the site of sigmoid colon fixation by radiological colongraphy then tip of artery forceps was moved at outer skin at anterior abdominal wall at left lower quadrant to meet tip of colonscopy at multiple point where fixation was done . fixation was done by exploratory puncture of skin by scalpel about (2-3 mm puncture) at site of these points then widening the puncture by artery forceps at level of subcutaneous tissue. A 2- shot anchor device was used to fix the sigmoid colon against anterior abdominal wall. The 2-shot anchor device was passed through the puncture to be entered inside the sigmoid colon and the thread with a metal T-bar was detachd and pulled towards the anterior abdominal wall. This was repeated at multiple point of fixation .
Study: NCT01339403

Intervention type: OTHER
Intervention: non-interventional trial
Description: No study specific intervention, non-interventional trial

Intervention type: OTHER
Intervention: non-interventional trial
Description: No study specific intervention, non-interventional trial
Study: NCT03238521

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal osteosynthesis with classical pedicle finder
Description: Posterior thoracic and lumbar osteosynthesis with classical pedicle finder

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal osteosynthesis with pedicle finder with impedancemetry
Description: Posterior thoracic and lumbar osteosynthesis with pedicle finder with impedancemetry
Study: NCT03333993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Exercise
Description: The Mat Pilates exercise will be performed twice a week and the duration of the sessions will be 60 minutes, consisting of 5 minutes of warm-up exercises, 50 minutes of strengthening exercises followed by 5 minutes of relaxation and stretching.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercises
Description: Exercises for upper limbs according to the institutional routine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercises
Description: Exercises for upper limbs according to the institutional routine.
Study: NCT00879086

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin Mesylate
Description: E7389 (eribulin mesylate) given at a dose of 1.4 mg/m\^2 as a 2 to 5 minute intravenous (IV) bolus on Days 1 and 8 of a 21-day cycle.~The Treatment Phase will include six cycles. Patients may enter the Extension Phase for additional cycles following the sixth cycle of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixabepilone
Description: Ixabepilone given at a starting dose of 32 or 40 mg/m\^2 (as per approved labeling) as a 3-hour IV infusion on Day 1 of a 21-day cycle.~The Treatment Phase will include six cycles. Patients may enter the Extension Phase for additional cycles following the sixth cycle of treatment.
Study: NCT02817659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Glucagon infusion